

HOSTED BY THE WORKING GROUPS OF THE STOP TB PARTNERSHIP

4th Annual New Tools Summit

Monday, 16 November 2026 · Windsor Marapendi Hotel, Rio de Janeiro, Brazil

Agenda *(preliminary)*

Registration and coffee — 08:45 – 09:15

Welcome and opening remarks — 09:15 – 09:30

Opening remarks
Lucica Ditiu, Stop TB Partnership

Community lessons and importance of access as a priority for new tools to end TB
Maxime Lunga, Club des Amis Damien (DRC) and TB survivor

Session 1 · Innovations in Treatment — 09:30 – 12:00

Welcome and introduction from the Working Group on New TB Drugs (WGND)
Zaid Tanvir, TB Alliance and WGND Secretariat

New drug regimens and trial updates from research consortia and sponsors
Gates Medical Research Institute (Chris Ford) · UNITE4TB (Jodie Schildkraut) · SMART4TB (Payam Nahid)
Otsuka Pharmaceutical Co. Ltd (Irina Kontsevaya) · Aurum Institute / RS Wallis Consulting LLC (Bob Wallis)

Coffee break — 10:30 – 10:50

New drug regimens and trial updates from research consortia and sponsors (continued)
TB Alliance (Lynn Connolly) · GlaxoSmithKline (David Barros)
US CDC Tuberculosis Trials Consortium (Eric Nuermberger)

Wrap-up from WGND
Zaid Tanvir

Remarks from the Global Drug-resistant TB Initiative (GDI)
Ignacio Monedero-Recuero, Action Damien and GDI Chair

Drug-resistant TB in war and complex emergencies: novelties in implementation and unmet research priorities
Ignacio Monedero-Recuero

Bedaquiline resistance and lessons learned for new TB medications introduction
Lorenzo Guglielmetti, IRCCS Sacro Cuore Don Calabria

Wrap-up from GDI
Ignacio Monedero-Recuero

Lunch (provided) — 12:00 – 13:00

Session 2 · Innovations in Diagnosis — 13:00 – 14:50

Welcome and introduction from the New Diagnostics Working Group (NDWG) and the Global Laboratory Initiative (GLI)
Daniela Cirillo, San Raffaele Scientific Institute and NDWG Co-Chair
Leen Rigouts, Institute of Tropical Medicine Antwerp and GLI Core Group

Experience with early programmatic implementation of TB near-point of care (NPOC) molecular tests in Cameroon
Valerie Flore Donkeng Donfack, Cameroon Pasteur Institute and GLI Core Group

From innovation to impact: Engaging private providers in the introduction and scale-up of new TB tools
Mohammed Yassin, Global Fund and PPM Working Group Chair

Innovative research priorities across the care cascade to end TB in children and adolescents
Chishala Chabala, University of Zambia and Vice-Chair, Childhood and Adolescent TB Working Group (recorded)

State of the art: pipeline of new diagnostics
Seda Yerlikaya, Heidelberg University

Innovator showcase: short presentations by innovating companies + panel Q&A
Ustar, Co-Dx, Pluslife, Coyote, SD Biosensor, Genes2Me, Genoscreen, Qiagen, Fluxus, Level 42 AI

Wrap-up from NDWG and GLI
Daniela Cirillo and Leen Rigouts

Stop TB Partnership award announcement — 14:50 – 15:00

Coffee break — 15:00 – 15:20

Session 3 · Innovations in Prevention

END TB TRANSMISSION INITIATIVE (ETTI): INFECTION PREVENTION AND CONTROL (IPC) — 15:20 – 16:10

Welcome and introduction from ETTi
Jerod Scholten, ETTi Core Group Member

Air filtration, purification and air quality sampling/warning advances
Paul Jensen, Final Approach Inc. and ETTi Secretariat

Advances in use of Far Germicidal Ultraviolet 222 nm light for reducing TB and other respiratory infections
Ed Nardell, Harvard Medical School

Case study in Peru on TB & respiratory infection prevention with architectural innovations
Isabel Milagros Ochoa Delgado, Peru National Institute of Child Health

Panel Q&A
All presenters

Wrap-up from ETTi
Jerod Scholten

Bio-break — 16:10 – 16:20

WORKING GROUP ON NEW TB VACCINES (WGNV) — 16:20 – 17:35

Welcome and introduction from WGNV
David Lewinsohn, Oregon Health & Science University and WGNV Chair

TB Vaccine R&D: State of the Field

- **Upstream and preclinical research**
  David Lewinsohn
- **Clinical development of new TB vaccines**
  Monde Muyoyeta, Centre for Infectious Disease Research in Zambia

Advancing the next generation of TB vaccines

- **Phase 1 vaccine candidates led by high-burden countries**
  LipovaxinS4-EAH (Neni Nurainy, PT BioPharma (Persero) [recorded])
  Ad5-105K (Ruijie Wang, CanSino) · RH119 (Yu Pang, Beijing Chest Hospital)
- **How do we identify and advance the next generation of TB vaccine clinical candidates?**
  Alexander Schmidt, Gates Foundation

Preparing for implementation

- **TB Vaccine Accelerator updates on country preparedness and readiness**
  Birgitte Giersing, World Health Organization
- **A community perspective: the potential of new TB vaccines and preparing for their introduction**
  Evaline Kibuchi, Stop TB Partnership-Kenya

Wrap-up from WGNV

Closing — 17:35 – 17:40